VectivBio


Ironwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. They focus on GI drug discovery, with a singular focus on GI conditions, and have a pipeline of products including Linzess. The company is committed to innovation, patient outcomes, and industry leadership. They also engage in various community and responsibility initiatives.

Industries

biotechnology
health-care
medical

Nr. of Employees

medium (51-250)

VectivBio

Basel, Basel-Stadt, Switzerland, Europe


Patents

Manufacture, formulation and dosing of apraglutide

US-11766470-B2

View Details

Products

Linaclotide (GI therapeutic agent)

An orally administered guanylate cyclase‑C agonist developed for treatment of certain gastrointestinal disorders, with clinical development and approvals documented in multiple markets.


Services

Two‑year fellowship programs for PharmD graduates focused on clinical development or global patient safety, providing hands‑on experience in pharmaceutical development and safety operations.

Paid internship program providing multidisciplinary, hands‑on experience in the biopharmaceutical industry for students at historically Black colleges and universities.

Expertise Areas

  • Gastrointestinal therapeutic development
  • Clinical trial management (Phase II/III, global)
  • Real-world evidence and outcomes research
  • Formulation and pharmaceutical development
  • Show More (4)

Key Technologies

  • Clinical trial design and operations
  • Real-world data analytics
  • Pharmaceutical formulation development
  • Regulatory submission workflows
  • Show More (1)

News & Updates

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.